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INTRODUCTION
The major serum metabolite of vitamin D (Vit D) is 25-hy-
droxyvitamin D (25[OH]D), which has been providing new 
insights into breast cancer. Compelling meta analyses have 
suggested that serum 25(OH)D concentrations are inversely 
associated with breast cancer development and increased risks 
of recurrence and death in patients with early-stage cancer 
[1,2]. A recent prospective cohort study also demonstrated 
that serum 25(OH)D levels were an independent prognostic 
factor in women with breast cancer [3]. However, contradic-
tory results have also been reported [4,5]. Furthermore, no ef-
fect of serum Vit D levels on the pathologic complete response 
(pCR) has been demonstrated in neoadjuvant settings [6,7]. 
Vit D is closely linked to various disease conditions, includ-
ing malignancy and skeletal health; Vit D deficiency is highly 
prevalent worldwide and an important threat to human health 
[8,9]. During treatment for breast cancer, serum 25(OH)D 
levels have been reported to dramatically change, with the 
main effect being decreased 25(OH)D concentrations, espe-
cially during chemotherapy [10,11]. Although dietary intake 
and ultraviolet B exposure are important factors influencing 
25(OH)D levels, Vit D supplements have been investigated for 
the purpose of cancer prevention and active forms are consid-
ered as adjuvants to chemotherapy for malignancies [8,12]. 
Therefore, it is worthwhile to explore the emerging roles of Vit 
D in patients with breast cancer. 
Herein, to address the association between serum 25(OH)D 
concentrations and the outcomes of patients with breast can-
cer treated with neoadjuvant chemotherapy (NCT), we exam-
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Purpose: We investigated the changes in serum 25-hydroxyvitamin 
D (25[OH]D) levels before and after neoadjuvant chemotherapy 
(NCT) and the associations with pathologic complete response 
(pCR) and survival in patients with breast cancer. Methods: Serum 
25(OH)D concentrations were measured pre- and post-NCT in 
374 patients between 2010 and 2013. Based on a cutoff of 20 
ng/mL, patients were categorized into “either sufficient” or “both 
deficient” groups. The associations with clinicopathological data, 
including pCR and survival, were analyzed using multivariable 
analyses. Results: Patients with either pre- or post-NCT sufficient 
25(OH)D levels accounted for 23.8%, and the overall pCR rate 
was 25.9%. Most patients showed 25(OH)D deficiency at diag-
nosis and 65.8% showed decreased serum levels after NCT. 
Changes in 25(OH)D status were associated with postmeno-
pause status, rural residence, baseline summer examination, 
and molecular phenotype, but not pCR. No association between 
survival and 25(OH)D status was found, including in the sub-
group analyses based on molecular phenotypes. Conclusion: 
Most Korean patients with breast cancer showed vitamin D defi-
ciency at diagnosis and a significant decrease in the serum con-
centration after NCT. No association with oncologic outcomes 
was found. Therefore, although optimal management for vitamin 
D deficiency is urgent for skeletal health, further research is war-
ranted to clearly determine the prognostic role of vitamin D in 
patients with breast cancer who are candidates for NCT.
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ined the sequential changes in serum 25(OH)D levels prior to 
and after receiving NCT and exploratively analyzed the asso-
ciations with pCR and survival in patients with breast cancer.
METHODS 
Demographics and serum 25(OH)D levels 
A total of 374 consecutive patients who received NCT and 
subsequently underwent definitive surgery of the breast and 
axilla between January 2010 and December 2013 were retro-
spectively selected. All patients in the study cohort were ex-
amined for their serum 25(OH)D levels both prior to and af-
ter receiving NCT. The serum 25(OH)D levels of the patients 
at baseline and after NCT were evaluated according to the 
manufacturer’s protocol at the Department of Nuclear Medicine, 
Severance Hospital, Seoul, Republic of Korea. A gamma counter 
(1470 Wizard; Perkin-Elmer, Turku, Finland) with a radioim-
munoassay (25-Hydroxyvitamin D 125I RIA Kit; DiaSorin, 
Stillwater, USA) was used to measure serum 25(OH)D concen-
trations. Using a cutoff of ≥ 20 ng/mL for sufficient 25(OH)D 
levels [13], the patients were categorized into the “both defi-
cient” group, wherein patients had deficient Vit D levels at 
baseline and after NCT, or the “either sufficient” group, 
wherein patients had sufficient Vit D levels either at baseline 
or after NCT.
The NCT regimen mainly comprised four cycles of anthra-
cycline plus cyclophosphamide (AC) followed by four cycles 
of taxane± titanium silicate-1 in 342 patients (91.4%). Four-
teen patients (3.7%) received AC alone or a cyclophospha-
mide, methotrexate, and fluorouracil regimen. Of the remain-
ing 18 patients (4.8%), 10 were treated with a taxane, carbo-
platin, and bevacizumab regimen; four with anthracycline 
plus taxane or a taxane, anthracycline, and cyclophosphamide 
regimen; and four with taxane plus trastuzumab. All patients 
received radiation therapy postoperatively, and endocrine 
therapy was initiated according to their hormone receptor sta-
tus. Among the 16 administrative districts of the Republic of 
Korea, the capital city (Seoul), surrounding metropolitan area 
(Gyeonggi), and six other metropolitan cities (Busan, Daegu, 
Incheon, Gwangju, Daejeon, and Ulsan) were categorized as 
urban. The remaining regions (Gangwon, Chungbuk, Chungnam, 
Jeonbuk, Jeonnam, Gyeongbuk, Gyeongnam, and Jeju) were 
categorized as rural. This study was approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University 
Health System, Seoul, Korea (IRB number: 4-2016-0367), and 
the need for written informed consent was waived.
Pathologic examination
The absence of in situ or invasive carcinomas or residual in 
situ carcinoma alone without invasive disease in the breast 
and no evidence of metastatic tumors in the axillary lymph 
nodes were considered an achievement of pCR post-NCT. 
Expression of biomarkers, including estrogen receptor (ER) 
and progesterone receptor (PR), was reviewed through pa-
thology reports. Positivity of hormone receptors was defined 
as tumors with ≥ 1% nuclear-stained cells on immunohisto-
chemistry assessment of biopsy specimens according to the 
American Society of Clinical Oncology/College of American 
Pathologists (ASCO/CAP) guidelines [14]. Human epidermal 
growth factor receptor 2 (HER2) immunostaining was scored 
from 0 to 3+ and in situ hybridization was performed in cases 
with HER2-equivocal results. Criteria for positivity of HER2 
followed the ASCO/CAP guidelines of HER2 testing [15]. The 
Ki-67 indexes were scored by counting the number of posi-
tively stained nuclei and were expressed as the percentage of 
total tumor cells. Ki-67 > 15% was used as a cutoff for high 
proliferative indexes.
Based on the ER, PR, and HER2 expressions and Ki-67 in-
dexes, the molecular phenotypes were categorized into the 
following four subgroups: luminal A-like (ER- and/or PR-
positive, HER2-negative, and Ki-67 ≤ 15%), luminal B-like 
(ER- and/or PR-positive, HER2-negative, and Ki-67 > 15%; or 
ER- and/or PR-positive and HER2-positive), HER2-enriched 
(ER-negative, PR-negative, and HER2-positive), and triple-
negative breast cancer (TNBC; ER-negative, PR-negative, and 
HER2-negative). In patients with unavailable Ki-67 results, 
histologic grade III was considered as high proliferation.
Statistical analysis
Differences between the groups according to clinicopathol-
ogical parameters were evaluated using the chi-square test, 
and Fisher exact test was applied when appropriate. The inde-
pendent t-test and one-way analysis of variance (ANOVA) 
with Bonferroni correction were used to compare the means 
of continuous numerical data. Disease-free survival (DFS) 
was measured from the date of curative surgery to the date of 
first locoregional or distant recurrence or death before any 
type of relapse. Overall survival (OS) was calculated from the 
date of first surgery to the date of last follow-up or death from 
any cause. Univariable associations between predefined events 
and parameters were assessed using the Kaplan-Meier meth-
od; the groups were compared using the log-rank test. The 
Cox proportional hazard model was used to identify variables 
independently associated with survival. All statistical tests 
were two-sided and p-values < 0.05 were considered statisti-
cally significant. SPSS version 23.0 (IBM Inc., Armonk, USA) 
was used for all analyses.
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RESULTS
Changes in serum 25(OH)D levels and patient characteristics
The mean age of all patients was 48.7± 9.7 years and the 
mean follow-up duration was 52.3± 16.5 months. The overall 
pCR rate was 25.9%. The median 25(OH)D levels were 12.94 
ng/mL (range, 3.57–46.28 ng/mL) at baseline and 10.52 ng/mL 
(range, 2.54–39.57 ng/mL) after NCT. The mean time interval 
of 25(OH)D examination between baseline and completion of 
NCT was 163 ± 19.6 days. At baseline, 63 patients (16.8%) 
showed sufficient 25(OH)D levels, and after the completion of 
NCT, 41 (11.0%) showed sufficient levels. Compared to base-
line 25(OH)D levels, 246 patients (65.8%) showed decreased 
25(OH)D levels after NCT (median difference before vs. after 
NCT, –2.69 ng/mL; range, –24.20 to 25.57 ng/mL). The “either 
sufficient” group comprised 89 patients (23.8%). In patients 
who achieved pCR, the mean serum 25(OH)D levels at base-
line and after NCT were 14.60 ng/mL and 12.68 ng/mL, re-
spectively. The mean 25(OH)D levels before and after NCT 
were 14.39 ng/mL and 11.87 ng/mL, respectively, in patients 
who did not achieve pCR. There were no differences in 
25(OH)D levels according to pCR (p= 0.795 at baseline and 
p= 0.314 after NCT). 
Table 1 shows the patient characteristics according to the 
25(OH)D levels prior to and after receiving NCT. The “either 
sufficient” group demonstrated higher proportions of post-
menopausal status, residence in rural areas, and baseline sum-
mer examinations. At completion of NCT, the “either suffi-
cient” group frequently underwent examinations of 25(OH)D 
levels in the autumn and winter seasons. The histopathologi-
cal features and treatment modalities are presented in Table 2. 
ER-negative and HER2-positive tumors were more common 
in the “either sufficient” than in the “both deficient” group. 
Therefore, the HER2-enriched subtype was significantly more 
frequent in the “either sufficient” group and endocrine ther-
apy was more frequently performed in the “both deficient” 
group. Other tumor-associated characteristics, including 
achievement of pCR or the Ki-67 proliferation index, did not 
differ. When the clinicopathological parameters were com-
pared according to 25(OH)D levels at baseline and after NCT, 
postmenopausal status, rural residence, examination in the 
summer season, and ER-negative and HER2-positive tumors 
were more frequent in patients with sufficient baseline 
25(OH)D concentrations. However, only the positive associa-
tion between ER-negativity and sufficient 25(OH)D concen-
trations after NCT was maintained when the clinicopatholog-
ical characteristics were compared according to the Vit D sta-
tus after NCT.
Survival analyses
DFS and OS curves according to 25(OH)D status are pre-
sented in Figure 1 and showed no statistical significance. 
When each 25(OH)D status before and after NCT was ana-
lyzed, no association with survival outcomes was determined. 
Achievement of pCR and the luminal A-like molecular phe-
notype were significant factors for improved survival (Supple-
mentary Figure 1, available online). Multivariable analysis 
demonstrated no significance of each or combined 25(OH)D 
statuses for survival (Table 3). Advanced stage III at diagnosis, 
high grade, non-pCR, and the molecular phenotype were in-
dependently associated with increased risks for poor DFS and 
OS (data not shown).
Subgroup analyses stratified by molecular phenotype 
Finally, the association between changes in 25(OH)D levels 
and survival was explored according to the stratification by 
molecular phenotype. Figure 2 shows the changes in 25(OH)
D levels during NCT according to the molecular phenotype 
and achievement of pCR. The mean baseline 25(OH)D levels 
Table 1. Patient characteristics according to the 25(OH)D levels prior to 
and after NCT
Parameter
Both deficient 
(n=285) 
No. (%)
Either sufficient 
(n=89) 
No. (%)
p-value
Age (yr) 0.334
   ≤40 65 (22.8) 16 (18.0)
   >40 220 (77.2) 73 (82.0)
Menopause 0.004
   Premenopause 165 (57.9) 36 (40.4)
   Postmenopause 120 (42.1) 53 (59.6)
Residence 0.043
   Urban 249 (87.4) 70 (78.7)
   Rural 36 (12.6) 19 (21.3)
BMI (kg/m2) 0.270
   <25 187 (65.6) 64 (71.9)
   ≥25 98 (34.4) 25 (28.1)
Examination season at baseline 0.004
   Winter (Dec–Feb) 79 (27.7) 17 (19.1)
   Spring (Mar–May) 63 (22.1) 20 (22.5)
   Summer (Jun–Aug) 55 (19.3) 33 (37.1)
   Autumn (Sep–Nov) 88 (30.9) 19 (21.3)
Examination season after NCT 0.038
   Winter (Dec–Feb) 53 (18.6) 23 (25.8)
   Spring (Mar–May) 93 (32.6) 19 (21.3)
   Summer (Jun–Aug) 72 (25.3) 17 (19.1)
   Autumn (Sep–Nov) 67 (23.5) 30 (33.7)
Change in 25(OH)D levels 0.516
   Decreased 190 (66.7) 56 (62.9)
   Increased 95 (33.3) 33 (37.1)
25(OH)D=25-hydroxyvitamin D; BMI=body mass index; NCT=neoadjuvant 
chemotherapy.
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were significantly higher in patients with the HER2-enriched 
subtype (17.67 ng/mL) than those in patients with the luminal 
A-like (13.51 ng/mL, p= 0.001), luminal B-like (13.89 ng/mL, 
p = 0.003), and TNBC (14.19 ng/mL, p = 0.022) subtypes. 
However, 25(OH)D concentrations highly decreased after 
NCT in patients with the HER2-enriched subtype and no dif-
ference in 25(OH)D levels after NCT was determined among 
the molecular phenotypes (luminal A-like, 11.56 ng/mL; lu-
minal B-like, 11.22 ng/mL; HER2-enriched, 13.78 ng/mL; and 
Table 2. Histopathology and treatment modalities according to the 
25(OH)D status
Parameter
Both deficient 
(n=285) 
No. (%)
Either sufficient 
(n=89) 
No. (%)
p-value
Histologic type 0.393*
   Ductal 273 (95.8) 83 (93.3)
   Lobular/special type 12 (4.2) 6 (6.7)
Regimens of NCT 0.548
   AC-T±TS-1 262 (91.9) 80 (89.9)
   Others, incl. targeted agents 23 (8.1) 9 (10.1)
Clinical tumor stage at diagnosis 0.936
   cT1 72 (25.3) 24 (27.0)
   cT2 166 (58.2) 50 (56.2)
   cT3–4 47 (16.5) 15 (16.9)
Clinical node stage at diagnosis 0.767
   cN0 23 (8.1) 6 (6.7)
   cN1 133 (46.7) 39 (43.8)
   cN2–3 129 (45.3) 44 (49.4)
Histologic grade 0.692
   I/II 211 (74.0) 64 (71.9)
   III 74 (26.0) 25 (28.1)
ER 0.040
   Positive 191 (67.0) 49 (55.1)
   Negative 94 (33.0) 40 (44.9)
PR 0.433
   Positive 119 (41.8) 33 (37.1)
   Negative 166 (58.2) 56 (62.9)
HER2 0.046
   Positive 86 (30.2) 37 (41.6)
   Negative 199 (69.8) 52 (58.4)
Ki-67 (%, n=308) 0.837
   ≤15 103 (43.8) 31 (42.5)
   >15 132 (56.2) 42 (57.5)
Molecular phenotype 0.037
   Luminal A-like 88 (30.9) 24 (27.0)
   Luminal B-like 104 (36.5) 26 (29.2)
   HER2-enriched 37 (13.0) 23 (25.8)
   TNBC 56 (19.6) 16 (18.0)
Postsurgical pathology 0.101
   pCR 68 (23.9) 29 (32.6)
   Non-pCR 217 (76.1) 60 (67.4)
Type of surgery 0.776
   Breast-conserving surgery 133 (46.7) 40 (44.9)
   Total mastectomy 152 (53.3) 49 (55.1)
Endocrine therapy 0.021
   Done 192 (67.4) 48 (53.9)
   Not done 93 (32.6) 41 (46.1)
Targeted therapy 0.277
   Done 82 (28.8) 31 (34.8)
   Not done 203 (71.2) 58 (65.2)
25(OH)D =25-hydroxyvitamin D; NCT =neoadjuvant chemotherapy; AC-
T=anthracycline plus cyclophosphamide followed by taxane; TS-1=titanium 
silicate-1; ER=estrogen receptor; PR=progesterone receptor; HER2=human 
epidermal growth factor receptor 2; TNBC=triple-negative breast cancer; 
pCR=pathologic complete response. 
*p-value was calculated by Fisher exact test.
Figure 1. Kaplan-Meier curves according to 25-hydroxyvitamin D 
(25[OH]D) status. Disease-free survival (A) and overall survival (B) curves 
are presented. The green line denotes patients with either sufficient 
25(OH)D level at baseline or after neoadjuvant chemotherapy (NCT) and 
the blue line represents those with deficient 25(OH)D levels at both 
baseline and after NCT. 
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TNBC subtypes, 13.04 ng/mL; ANOVA with Bonferroni cor-
rection, p > 0.05). There was no statistical difference in 
25(OH)D levels between patients who achieved pCR and 
those who did not achieve pCR, irrespective of the molecular 
phenotype. The mean levels of 25(OH)D decreased in patients 
after NCT compared to those in patients at baseline, irrespec-
tive of the responsiveness to NCT or molecular phenotypes. 
Figure 3 demonstrates no differences in DFS and OS accord-
ing to 25(OH)D status stratified by molecular phenotype.
DISCUSSION
In this study, 83.2% of patients (311/374) with breast cancer 
were determined to have Vit D deficiency at diagnosis and 
only 12 patients (3.2%) showed 25(OH)D levels of ≥ 30 ng/
mL. After completion of NCT, 91.6% (285/311) still had defi-
cient Vit D levels and only 23.8% (15/63) maintained suffi-
cient 25(OH)D concentrations. Asian countries, including 
China, India, and Mongolia, have high prevalence rates of Vit 
D deficiency, and in Korea, 63.8% of women with a self-re-
ported history of cancer and 73.4% of women without a can-
cer history show deficient Vit D status [9,16]. Although the 
sample size in the NEOZOTAC trial was small, the prevalence 
of Vit D deficiency increased from 38.3% before initiating 
NCT to 55.9% at the end of NCT, with a change in the Vit D 
level of –16.0 nmol/L (–6.4 ng/mL) after NCT [7]. Similarly, 
adjuvant chemotherapy is associated with decreased 25(OH)D 
concentrations of –5.52 ng/mL at 6 months and –1.24 ng/mL at 
Figure 2. Changes in the 25-hydroxyvitamin D (25[OH]D) levels during neoadjuvant chemotherapy (NCT) stratified by molecular phenotype. Spaghetti 
plots showing the serum 25(OH)D levels at baseline and after completion of NCT in the luminal A-like (A), luminal B-like (B), human epidermal growth 
factor receptor 2 (HER2)-enriched (C), and triple-negative breast cancer (TNBC) (D) phenotypes. The red line exhibits patients who achieved a pathologic 
complete response (pCR) and the blue line denotes those who did not achieve a pCR after NCT. 
SD=standard deviation.
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Table 3. Multivariable analysis for survival
Multivariable model
Disease-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
Model 1*
   25(OH)D status (both insufficient) 1.305 0.655–2.601 0.448 1.033 0.456–2.340 0.937
Model 2†
   25(OH)D at baseline (insufficient) 0.998 0.461–2.163 0.997 0.561 0.237–1.328 0.188
   25(OH)D after NCT (insufficient) 1.849 0.632–5.415 0.262 2.911   0.651–13.016 0.162
HR=hazard ratio; CI=confidence interval; 25(OH)D=25-hydroxyvitamin D; NCT=neoadjuvant chemotherapy.
*In model 1, the serum 25(OH)D level before and after NCT was used in the multivariable analyses; †In model 2, each 25(OH)D status prior to or after NCT was en-
tered into the multivariable analyses. Age, clinical stage at diagnosis, histologic grade, molecular phenotype, postsurgical pathology, type of surgery, endocrine 
therapy, and targeted therapy were adjusted in each multivariable model.
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Figure 3. Kaplan-Meier curves accord-
ing to the 25-hydroxyvitamin D (25[OH]
D) status stratified by molecular phe-
notype. Disease-free survival (A, C, E, 
and G) and overall survival (B, D, F, 
and H) curves are presented in the 
luminal A-like (A and B), luminal B-like 
(C and D), human epidermal growth 
factor receptor 2 (HER2)-enriched (E 
and F), and triple-negative breast can-
cer (G and H) phenotypes. The green 
line shows patients with either suffi-
cient 25(OH)D level at baseline or after 
neoadjuvant chemotherapy (NCT) and 
the blue line exhibits those with defi-
cient 25(OH)D at both baseline and af-
ter NCT. 
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12 months [11]. However, daily supplements of Vit D3 (400 
IU) for 1 year in patients with premenopausal status modestly 
increased 25(OH)D levels and partially prevented a decrease 
in serum concentrations by chemotherapy [17]. 
It has not been clearly determined whether chemotherapy 
directly affects changes in serum 25(OH)D levels, plays indi-
rect roles through gastrointestinal side effects and behavioral 
changes toward avoiding sunlight exposure, or whether 
25(OH)D concentrations are not significantly affected by che-
motherapy [7,10,17]. Miyoshi et al. [18] suggested that 
docetaxel could upregulate the cytochrome P450 3A4 en-
zyme, which might convert active forms of Vit D to inactive 
metabolites. The administration of corticosteroids as anti-
emetics during chemotherapy or estrogen deprivation by che-
motherapy-induced amenorrhea might partially affect Vit D 
metabolism and serum concentrations [11].
In addition to dietary intake, supplementation, and sun-
light, serum 25(OH)D levels are influenced by many genetic, 
environmental, and lifestyle factors, including genetic poly-
morphisms, race, ethnicity, age, sex, pregnancy, season, body 
mass index, pregnancy, skin pigmentation, and hereditary and 
acquired disorders, such as liver failure or chronic renal dis-
ease [19,20]. The anticancer actions of Vit D signaling are ex-
erted via antiproliferation, anti-inflammation, anti-invasion 
and metastasis, antiangiogenesis, and induction of apoptosis 
and differentiation [21,22]. Calcitriol, an active Vit D form, 
has various functions through endocrine, paracrine, or auto-
crine modes. After binding to Vit D or retinoid X receptors, 
calcitriol plays a role via both genomic and nongenomic ac-
tions [23]. The net effects of altered gene expression are bene-
ficial antitumor effects [2]. ER pathways may be influenced by 
calcitriol, like the suppression of aromatase in adipose tissues 
and the suppression of ER or estrogen-mediated signaling in 
cancer cells [24]. In patients with breast cancer, Vit D defi-
ciency is associated with aggressive prognostic features, in-
cluding advanced tumor stage, high grade, high Ki-67 index-
es, or negative ER expression [3,25,26]. Consistently, our study 
demonstrated that the “either sufficient” group was associated 
with postmenopausal status, rural residence, summer exami-
nations, and molecular phenotypes. However, the body mass 
index, stage, grade, and Ki-67 index were not different be-
tween the groups. More comprehensive studies are necessary 
to determine the associations between serum 25(OH)D levels 
and clinicopathological characteristics in breast cancer.
Recent studies of the impact of Vit D on the responsiveness 
to NCT showed no significant association of serum 25(OH)D 
levels with pCR, similarly to that determined in our study 
[6,7]. When stratified by molecular phenotype, changes in Vit 
D status are not a predictive factor for pCR. Although the 
baseline patient characteristics differed from those in our 
study, patients with a favorable response of > 90% decrease in 
tumor cells showed increased serum Vit D levels at the end of 
NCT [7]. Based on in vitro cell line and animal experiments, 
calcitriol has been shown to increase chemotherapy-induced 
cell death; however, in the in vivo milieu, the tumoricidal ef-
fects exerted by chemotherapeutic agents might be more 
complex [6]. As we could not evaluate Vit D receptor expres-
sion in the cancer tissues, further studies are required to con-
clude the association between serum Vit D concentrations 
and pCR in neoadjuvant settings.
Additionally, the present study demonstrated no clinical as-
sociation between 25(OH)D status and survival in patients 
with breast cancer treated with NCT. Irrespective of the mo-
lecular phenotype, changes in 25(OH)D levels were not a 
prognostic factor. Although the follow-up duration of our co-
hort was relatively short, subgroup analysis from the I-SPY 
trial similarly determined no evidence of Vit D levels as a 
prognostic factor [6]. However, previous meta analyses 
showed that high 25(OH)D levels were significantly associat-
ed with lower risks of breast cancer mortality and overall 
death in adjuvant settings [27,28]. On the contrary, an adju-
vant clinical trial showed no evidence of the association be-
tween Vit D blood levels and relapse-free survival, breast can-
cer-specific survival, or OS [5]. More research should be con-
ducted to determine the implications of 25(OH)D levels on 
survival outcomes in patients with breast cancer receiving 
NCT. 
A strength of our study is the relatively large sample size 
with paired evaluation of serum 25(OH)D concentrations be-
fore initiation and after completion of NCT. We also analyzed 
the prognostic power of Vit D levels according to molecular 
phenotype. However, the retrospective nature and relatively 
short follow-up period are important limitations. Further, we 
could not assess several confounding factors for serum 
25(OH)D concentrations, including dietary intake, supple-
ments, application of sunblock, or physical activity. Finally, for 
the definition of molecular phenotype, Ki-67 indexes were 
substituted with histologic grade in 17.6% of cases.
In conclusion, Vit D3 deficiency was highly prevalent at the 
time of diagnosis in Korean patients with breast cancer and a 
significant decrease in serum 25(OH)D levels was demon-
strated after completion of NCT. Sufficient 25(OH)D status 
either before or after NCT was not significantly associated 
with a favorable response to NCT or improved survival out-
comes. Therefore, correction or maintenance of appropriate 
serum Vit D3 levels as comprehensive management of pa-
tients receiving NCT should be urgently focused on for skele-
tal health, but not for oncological outcomes until more evi-
Serum 25-Hydroxyvitamin D and Breast Cancer Survival after Neoadjuvant Chemotherapy 141
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dence is accumulated. Additionally, the possible oncological 
aspects of Vit D3 should be further explored and researched 
comprehensively considering breast cancer subtypes.
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